Astrazeneca Ab

Imperial Chemical Industries Limited

Zeneca Limited

Ici Pharma

Robert Hugh Bradbury

David A Roberts

Alfred Arthur Rabow

James Francis McCabe

Arnold H Ratcliffe

Michael James Waring

Roger James

Elizabeth Janet Pease

Zoe Ann Cotter

Steven Christopher Glossop

Arshed Mahmood

Andrew Peter Thomas

Laurent Francois Andre Hennequin

Jason Grant Kettle

Gloria Anne Breault

Roger John Butlin

Robert J Pearce

Heather Marie Redfearn

David Buttar

Martin P Edwards

Christopher De Savi

Craig Samuel Donald

Gordon Stuart Currie

Nadim Akhtar

Emma Jane Williams

Helen Elizabeth Williams

Matthew Osborne

Neda Yavari

Richard Albert Norman

Frederic H Jung

Peter R Marsham

Jean J Lohmann

Stuart Eric Pearson

Georges Pasquet

David Waterson

Bernard Christophe Barlaam

Jeffrey James Morris

David J Brown

Neil James Hales

Janet Elizabeth Pease

Andrew Turner

Paul J Phillips

Richard Ducray

Richard William Luke

Philip J Jewbury

Peter Grahame Ballard

Gregory Richard Carr

Srinivasa Rao Korupoju

Harikrishna Tumma

James Francis Mccabe

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R, Rand n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.

[1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases

[1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein Rto Rhave any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Chemical compounds

The invention concerns compounds of Formula (I) (Formula (I)) or pharmaceutically-acceptable salts thereof, wherein R, Rand n have any of the meanings defined herein before in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents. 

The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein Rto Rhave any of the meanings defined hereinbefore in the description: processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

The invention concerns quinazoline derivatives of Formula (I) wherein each of Q, Z, Rand Qhave any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases. 

4-anilino quinazoline derivatives as antiproliferative agents

The invention concerns bicyclic compounds of Formula I wherein, R, R, L, L, J, Y, k, n, p and r are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen-receptor associated conditions, particularly prostate cancer.

Chemical compounds&#x2014;643

The invention concerns bicyclic compounds of Formula I wherein the integers X, X, X, Ring A, R, Rand m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.

Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155

A quinazoline derivative of the Formula I: 

4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer

A quinazoline derivative of the Formula (I): wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man. 

Quinazoline derivatives

The invention concerns quinazoline derivatives of Formula I wherein Rand Rhave any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB, particularly EGF, receptor tyrosine kinases.

Pyrimidine derivatives of formula (I) wherein Q, Q, G and Rare as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.

2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents

2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents

Growing community of inventors

Macclesfield, United Kingdom

Robert Hugh Bradbury